Investment writer Tony Cross picks out three things you need to know about the markets. This morning, Tony's focus is on Tasty plc, Novacyt and Mears GroupContinue reading Three...
Novacyt S.A. (NVYTF): FY GAAP EPS of£1.94.Revenue of£277.2M (+2310.4% Y/Y)Gross margin increased to 76.3% in 2020 from 64.0% in 2019.EBITDA increased to £176.1M in...
Investment writer Tony Cross picks out three things you need to know about the markets. This morning, Tony's focus is on DS Smith, Novacyt and National ExpressContinue reading...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Neutral |
| Technical Indicators | Neutral | Strong Sell | Buy | Strong Sell | Strong Sell |
| Summary | Sell | Strong Sell | Neutral | Strong Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 8.96 | 8.97 | 8.60 | +0.26 | +3.05% | 1.35M | London | |||
| 482.40 | 486.20 | 466.20 | -7.60 | -1.55% | 289.12K | London | |||
| 99.71 | 101.14 | 98.30 | -2.47 | -2.42% | 32.29M | London | |||
| 116.18 | 117.10 | 115.24 | -0.22 | -0.19% | 50.32M | London | |||
| 7,490.00 | 7,492.00 | 7,238.00 | +172.0 | +2.35% | 641.73K | London | |||
| 3,190.50 | 3,246.50 | 3,173.50 | -102.5 | -3.11% | 3.41M | London | |||
| 261.00 | 265.60 | 247.90 | -7.80 | -2.90% | 13.02M | London | |||
| 3,400.00 | 3,402.00 | 3,339.00 | +24.0 | +0.71% | 321.92K | London | |||
| 45.63 | 46.33 | 45.38 | -0.56 | -1.22% | 164.24M | London | |||
| 225.40 | 228.50 | 224.30 | -2.10 | -0.92% | 7.21M | London | |||
| 1,192.50 | 1,212.00 | 1,185.00 | -12.00 | -1.00% | 194.07K | London | |||
| 966.00 | 972.00 | 961.00 | -4.00 | -0.41% | 192.84K | London | |||
| 164.60 | 166.15 | 164.00 | -1.45 | -0.87% | 6.02M | London | |||
| 1,494.50 | 1,523.50 | 1,491.00 | -38.00 | -2.48% | 744.19K | London | |||
| 255.90 | 297.30 | 253.60 | -48.80 | -16.02% | 12.30M | London |
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Lab21 Products, IT-IS International, and Primerdesign segments. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The Primerdesign segment designs, manufactures, and markets molecular ‘real-time’ qPCR testing devices and reagents in the areas of infectious diseases. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. The company’s diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves public hospitals, central laboratories, private testing, and mobile laboratories. Novacyt S.A. was incorporated in 2006 and is headquartered in Camberley, the United Kingdom.
